Reprogramming Cancer And Competing With China With Earli's Cyriac Roeding
From Business Of Biotech · · 59 min
This plays from the publisher's own server. We do not host a copy.
Description
We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1011661/fan_mail/new)
On this week's episode of the Business of Biotech, Cyriac Roeding talks about cofounding and leading Earli, a "bioAI" company using synthetic DNA switches and cancer-binding lipid nanoparticles to transform cancer cells into immune therapy-producing factories in vivo. Cyriac also discusses China’s newest five-year plan for biotech (2026 to 2030), why U.S. funding cycles are pushing innovation offshore, and how a U.S. sovereign wealth fund could support preclinical and early-stage drug development leadership at home.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech (https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl) tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter (https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/).
Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/